By Fineline Cube 
China-based advanced therapy medicinal product (ATMP) contract development and manufacturing organization (CDMO) uBriGene Biosciences announced the appointment of Dr. Joy Zhou as Vice President of Cell Therapy. In her new role, Dr. Zhou will oversee the development of the company’s cell therapy production technology platform, cGMP production, and quality control.
Expansion and Technology Transfer
Dr. Zhou will lead the expansion of uBriGene’s cell therapy development and production capabilities at its US production base. She will also optimize solutions for transferring customer processes between production facilities in China and the United States, further accelerating the industrialization of cell therapy in both markets.
Expertise and Background
With over 20 years of experience in the full lifecycle development of biopharmaceuticals, Dr. Zhou brings extensive expertise in key areas such as biologics, cell therapy, virus development, registration, and commercialization. Her specialized knowledge spans multiple cell therapy fields, including red blood cells, induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), tumor-infiltrating lymphocytes (TILs), and CAR-T/NK therapies.-Fineline Info & Tech